Werewolf Therapeutics sells preclinical platforms to EMD Serono for $28M upfrontAug 20PartnershipWerewolf Therapeutics, Inc.WTX-124
Werewolf posts Q2 2026 net income after Jazz deal, sets H2 update plans for WTX-124, WTX-330Jul 31Quarterly updateJazz PharmaceuticalsWerewolf Therapeutics, Inc.
Sign inSign in